For instance, the promising results of the use of the c-MET inhibitor crizotinib in NSCLC cell lines harboring MET amplification, a known MOR to osimertinib, has shown a potential to overcome the acquired resistance [82,83]. This evidence concerns the gene MET and non-small cell lung carcinoma.